BRIEF-Nano Dimension Signs Term Sheet With Infinite Epigenetics To Form A Publicly Traded, AI-Powered Preventive Health And Diagnostics Company

June 15 (Reuters) - Nano Dimension Ltd 2N5By.F:

  • NANO DIMENSION SIGNS TERM SHEET WITH INFINITE EPIGENETICS TO FORM A PUBLICLY TRADED, AI-POWERED PREVENTIVE HEALTH AND DIAGNOSTICS COMPANY

  • NANO DIMENSION - INFINITE EPIGENETICS DEAL VALUED AT $890 MILLION

  • NANO DIMENSION - SHAREHOLDERS TO RETAIN MINORITY OWNERSHIP AT 20% PREMIUM TO ESTIMATED NET CASH

  • NANO DIMENSION - MATTHEW DAWSON EXPECTED TO SERVE AS CEO OF COMBINED COMPANY

  • NANO DIMENSION - PRE-COMBINATION NANO DIMENSION SHAREHOLDERS TO RECEIVE CONTINGENT VALUE RIGHT FOR LEGACY ASSET SALES

Source text: ID:nGNX7jcvw

Further company coverage: [2N5By.F]


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.